about
A planning comparison of 7 irradiation options allowed in RTOG 1005 for early-stage breast cancer.Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy.Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical resultsBreast irradiation and lactation: a review.What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer.Therapeutic analysis of Intrabeam-based intraoperative radiation therapy in the treatment of unicentric breast cancer lesions utilizing a spherical target volume model.Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial.A unique hypofractionated radiotherapy schedule with 51.3 Gy in 18 fractions three times per week for early breast cancer: outcomes including local control, acute and late skin toxicity.Durable Local Control Following Concurrent Hypofractionated Chemoradiation for a Massive Inflammatory Breast Cancer Chest Wall Recurrence.Comparison of Conventional and Hypofractionated Radiotherapy in Breast Cancer Patients in Terms of 5-Year Survival, Locoregional Recurrence, Late Skin Complications and Cosmetic ResultsMathematical optimization of the combination of radiation and differentiation therapies for cancer.Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important?Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation.Optimal number and sizes of the doses in fractionated radiotherapy according to the LQ model.Hypofractionated boost after whole breast irradiation in breast carcinoma: chronic toxicity results and cosmesis.Establishing the Role of Stereotactic Ablative Body Radiotherapy in Early-Stage Breast Cancer.Cancer Cell Death-Inducing Radiotherapy: Impact on Local Tumour Control, Tumour Cell Proliferation and Induction of Systemic Anti-tumour Immunity.Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.Once-Weekly Hypofractionated Radiotherapy for Breast Cancer in Elderly Patients: Efficacy and Tolerance in 486 Patients.Personal perspectives on the evolution of radiation therapy and future outlook for SRS.The use of helical tomotherapy in the treatment of early stage breast cancer: indications, tolerance, efficacy-a single center experience.Hypofractionated radiotherapy after conservative surgery may increase low-intermediate grade late fibrosis in breast cancer patients
P2860
Q36303421-09F03876-6D97-4A13-854B-D919CD065A9EQ36368120-961C585D-A526-4060-8C16-C288D82A22E8Q37212677-1128393F-9C0E-4B8F-BCED-4C312B40682BQ37263260-76F885C9-F508-44D1-B81F-CE627FC8F36CQ38081241-EEE99AEB-69C6-4FE2-A07B-F1104CFB8963Q38172228-835E8B6A-8FD5-4464-8D1D-281164D54545Q38662704-82498D22-75A1-4C92-B3FA-F1A8529A424AQ38811255-F26E0106-9BEA-4720-86B9-09F420C31A2BQ39839339-E0AB28AA-D0FB-4EE5-A2C0-D888098B5269Q41091686-E3E929AC-44B0-4E83-A44A-0F22E0D12F94Q42144060-5F870409-B0CE-4113-8DD0-37978156E5AFQ43226517-F890C173-3CBB-42B8-83AA-DD24CAC77311Q43775129-08DE2B99-C468-44F6-810C-0E88DA2FC747Q46342791-6AC40E54-A20E-4BB1-97CF-85BA313443C6Q47560995-270EE468-5BBE-4562-9125-3C5B0188D74CQ48341449-EF650D7E-84BD-4D68-8A05-342AB486E3E9Q50319353-20AB3C83-7504-45DF-9671-F49005C2B916Q51551651-F60CEA58-9153-482A-9DA3-FE74FCE5EF81Q52650717-AA6ACB95-8F92-4AC1-B25B-3F6E90710AC7Q55033689-0F372D6A-08E2-48AE-9BD6-BCC227F486B5Q55135169-294B4D0A-C959-485E-A6DF-72454ED91616Q55317264-6631B436-BBCA-4070-AFB1-1825797F6E5CQ55411386-FDF137F0-B454-442C-A1D2-6862D35814A8Q57484407-92E39E00-CCFF-4BC2-A38B-042DA71A4026
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Is α/β for breast cancer really low?
@en
Is α/β for breast cancer really low?
@nl
type
label
Is α/β for breast cancer really low?
@en
Is α/β for breast cancer really low?
@nl
prefLabel
Is α/β for breast cancer really low?
@en
Is α/β for breast cancer really low?
@nl
P2093
P1476
Is α/β for breast cancer really low?
@en
P2093
Julia White
X Allen Li
X Sharon Qi
P304
P356
10.1016/J.RADONC.2011.01.010
P577
2011-02-28T00:00:00Z